Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 2/20 | 0.41 |
| ▸ | SKP1 | P63208 | 2/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.39 |
| ▸ | ACACB | O00763 | 5/20 | 0.39 |
| ▸ | ACACA | Q13085 | 5/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29673283 | 0.87 | CKS1B (0.40) | L3MBTL1CKS1BSKP1SKP2ACACB | |
| SCHEMBL29070067 | 0.87 | CKS1B (0.40) | L3MBTL1CKS1BSKP1SKP2ACACB | |
| SCHEMBL31396268 | 0.85 | GPR119 (0.43) | CKS1BSKP1SKP2PDE10AACACB | |
| SCHEMBL23705898 | 0.84 | ALDH1A1 (0.42) | L3MBTL1ALDH1A1HPGDSMN1; SMN2MCHR1 | |
| SCHEMBL31401186 | 0.83 | SHMT2 (0.47) | PDE10AMAP4K4ALDH1A1 | |
| SCHEMBL31395918 | 0.83 | CA1 (0.37) | L3MBTL1CKS1BSKP1SKP2PDE10A | |
| SCHEMBL31401097 | 0.82 | HDAC1 (0.44) | CKS1BSKP1SKP2MAP4K4ACACB | |
| SCHEMBL23705506 | 0.80 | KDM4A (0.42) | L3MBTL1ACACBACACACA12CA1 | |
| SCHEMBL29673308 | 0.80 | KDM4A (0.42) | L3MBTL1ACACBACACACA12CA1 | |
| SCHEMBL29673310 | 0.80 | KDM4A (0.42) | L3MBTL1ACACBACACACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441726-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| CN-115297861-B | Compounds and uses thereof | 福宏治疗公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| EP-4096667-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-115297861-A | Compound and use thereof | 福宏治疗公司 | 2022-11-04 | — | — | CN | disclosed |
| WO-2021155320-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441726-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | L3MBTL1 1010/4885CKS1B 1519/4885SKP1 4430/4885 |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | L3MBTL1 1010/4885CKS1B 1519/4885SKP1 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.